Surmodics, Inc. (NASDAQ:SRDX) Stock Holdings Boosted by Gabelli Funds LLC

Gabelli Funds LLC increased its stake in Surmodics, Inc. (NASDAQ:SRDX - Free Report) by 3.7% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 339,959 shares of the company's stock after buying an additional 12,250 shares during the quarter. Gabelli Funds LLC owned about 2.38% of Surmodics worth $13,462,000 as of its most recent filing with the SEC.

Several other hedge funds have also modified their holdings of the stock. Barclays PLC grew its stake in Surmodics by 21.7% during the 4th quarter. Barclays PLC now owns 108,001 shares of the company's stock valued at $4,278,000 after purchasing an additional 19,251 shares in the last quarter. Legal & General Group Plc increased its position in shares of Surmodics by 34.2% in the 4th quarter. Legal & General Group Plc now owns 3,452 shares of the company's stock worth $137,000 after purchasing an additional 880 shares during the last quarter. Polymer Capital Management US LLC acquired a new stake in shares of Surmodics in the 4th quarter valued at about $255,000. Yakira Capital Management Inc. grew its stake in Surmodics by 103.2% in the fourth quarter. Yakira Capital Management Inc. now owns 71,113 shares of the company's stock worth $2,816,000 after purchasing an additional 36,113 shares in the last quarter. Finally, Wells Fargo & Company MN increased its holdings in Surmodics by 40.9% in the fourth quarter. Wells Fargo & Company MN now owns 7,032 shares of the company's stock valued at $278,000 after buying an additional 2,041 shares during the last quarter. 96.63% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on SRDX shares. Lake Street Capital upgraded Surmodics from a "hold" rating to a "buy" rating and set a $43.00 price target for the company in a report on Friday, March 7th. StockNews.com initiated coverage on shares of Surmodics in a research report on Monday, February 3rd. They issued a "hold" rating on the stock. Finally, Needham & Company LLC reiterated a "hold" rating on shares of Surmodics in a research note on Thursday, January 30th. Four equities research analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of "Hold" and an average price target of $50.00.

Surmodics Stock Performance

NASDAQ:SRDX traded down $0.08 during mid-day trading on Tuesday, hitting $28.47. The stock had a trading volume of 17,133 shares, compared to its average volume of 277,252. Surmodics, Inc. has a 52 week low of $25.17 and a 52 week high of $42.44. The company has a current ratio of 5.45, a quick ratio of 4.29 and a debt-to-equity ratio of 0.26. The stock has a market capitalization of $407.01 million, a price-to-earnings ratio of -28.19 and a beta of 1.30. The company has a 50 day simple moving average of $30.41 and a 200-day simple moving average of $35.45.

Surmodics (NASDAQ:SRDX - Get Free Report) last posted its earnings results on Thursday, February 6th. The company reported ($0.04) EPS for the quarter, beating the consensus estimate of ($0.08) by $0.04. Surmodics had a negative return on equity of 4.39% and a negative net margin of 11.48%. On average, research analysts expect that Surmodics, Inc. will post 0.2 earnings per share for the current fiscal year.

Surmodics Profile

Surmodics, Inc, together with its subsidiaries, provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates through two segments, Medical Device and In Vitro Diagnostics (IVD).